IFLR1000

AC Immune $99.9 million share offer

25/7/2018
Share offer
Select tab

$ 99.9 million

Announced

25/7/2018

Overview:

  • AC Immune is a Swiss biopharmaceutical company focused on neurodegenerative diseases. 

Mihail Georgiev - Data analyst

Jurisdiction:

Switzerland

Deal type:

Share offer

Practice area:

Capital markets : Equity

Governing law:

Switzerland

Industry sector:

Pharmaceuticals and life sciences

Firms:
Davis Polk & Wardwell

Party: AC Immune SA (Issuer)

Lawyers: Derek Dostal, Derek Dostal

Homburger

Party: Jefferies (Joint bookrunner)

Party: Leerink Partners (Joint bookrunner)

Party: UBS Investment Bank (Joint bookrunner)

Party: HC Wainwright (Lead manager)

Lawyers: Benjamin Leisinger, Dieter Gericke, Margrit Marti

Related deals